home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

235 rows where filing_period = "third_quarter", filing_year = 2014 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 235 ✖

filing_year 1

  • 2014 · 235 ✖

filing_period 1

  • third_quarter · 235 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1549209 DICKSTEIN SHAPIRO LLP 8e982702-3f7a-4d33-a392-5982e9fae86f 3T DICKSTEIN SHAPIRO LLP 12208 VERIMED, LLC 2014 third_quarter PHA Monitor legislative and administrative action regarding prescription drug abuse and diversion policies. H.R. 4486, Military Construction Veterans Affairs and Related Agencies Appropriations Act, 2015. Draft, Senate Military Construction Veterans Affairs and Related Agencies Appropriations Act, 2015. S. 2450, Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014. Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 10000   0 1 2014-07-11T22:41:11.567000-04:00
1581051 CYBER SECURITY RESEARCH CONSULTANTS, LLC 83b8ae7f-62ef-4cbf-9f20-c4b968460265 3T CYBER SECURITY RESEARCH CONSULTANTS, LLC 91694 PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2014 third_quarter PHA Monitoring Drug Importation Legislation FY 15 Agriculture Appropriations Bills HOUSE OF REPRESENTATIVES 15000   0 1 2014-09-22T07:46:43.450000-04:00
1581533 AMERICAN COLLEGE OF CLINICAL PHARMACY 0c714982-b3c0-4542-8e5a-0c4c017333bf Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2014 third_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   145515 0 0 2014-10-02T15:46:34.253000-04:00
1581736 MR. JOHN COSTER 4c7e2482-a3e6-4920-a7ba-d5311207e1a1 Q3 MR. JOHN COSTER 401103305 AMERISOURCE BERGEN 2014 third_quarter PHA HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014   7500   0 0 2014-10-05T09:39:18.210000-04:00
1581740 MR. JOHN COSTER 23e5c289-84a1-4c09-995e-41080f75aba0 Q3 MR. JOHN COSTER 401103305 AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS 2014 third_quarter PHA Pharmacy provider status issues, particularly HR 4190, Medicare Coverage of Pharmacy Services White House Office 13500   0 0 2014-10-05T10:01:21.387000-04:00
1581742 MR. JOHN COSTER be5ec638-e1c1-4ebe-81da-b23fe2425f2f 3A MR. JOHN COSTER 401103305 AMERISOURCE BERGEN 2014 third_quarter PHA HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014   15000   0 0 2014-10-05T10:02:22.187000-04:00
1581746 MR. JOHN COSTER fb93eec4-0199-4de7-acb4-39f3d07de59c Q3 MR. JOHN COSTER 401103305 HORIZON GOVERNMENT AFFAIRS 2014 third_quarter PHA medication therapy management legislation,particulary HR 1024 and S 557   7500   0 0 2014-10-05T10:11:25.143000-04:00
1581787 INJURED WORKERS PHARMACY 2184dfa3-b84c-433c-86c0-35428611fc6c Q3 INJURED WORKERS PHARMACY 400765309 INJURED WORKERS PHARMACY 2014 third_quarter PHA n/a HOUSE OF REPRESENTATIVES,SENATE     0 0 2014-10-06T08:58:44.930000-04:00
1582038 AMERICAN COLLEGE OF CLINICAL PHARMACY a0e193af-7ae1-4196-b869-c9177318bb25 3A AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2014 third_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   145515 0 0 2014-10-06T15:48:08.340000-04:00
1582052 RED+BLUE STRATEGIES d63966d0-673e-4d77-ab6c-7da99e75d932 Q3 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2014 third_quarter PHA H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy. Rules, regulations and guidance specific to prescription drug pricing, generic utilization, biosimilars and specialty pharmacy. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in naming policies for upcoming biosimilars. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefit. Issues regarding prescription drug coverage for public benefit programs. Issues related to Part D coverage for Medicare beneficiaries in hospice care. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-06T16:04:11.580000-04:00
1582656 KENT & O'CONNOR, INC. 7bfe79f6-35d8-4b3b-8c55-fd98d31ec69c Q3 KENT & O'CONNOR, INC. 21426 INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION 2014 third_quarter PHA Legislation and regulations relating to drug safety issues. Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection 30000   0 0 2014-10-08T11:45:17.283000-04:00
1583065 CHAMBER HILL STRATEGIES fd70eea3-2930-4807-be10-ecdbd3aa1096 Q3 CHAMBER HILL STRATEGIES 400645947 AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) 2014 third_quarter PHA Implementation issues related to P.L. 113-54, the Drug Quality and Security Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-08T17:27:21-04:00
1583136 HEARTLAND SOLUTIONS GROUP, INC. 15212594-71f6-4918-8f43-166da5f1e84e Q3 HEARTLAND SOLUTIONS GROUP, INC. 312133 ZEBRA TECHNOLOGIES CORPORATION 2014 third_quarter PHA Any and all issues related to labeling of generic drugs. HOUSE OF REPRESENTATIVES,SENATE 9000   0 0 2014-10-09T01:42:56.270000-04:00
1583228 RED+BLUE STRATEGIES d7ab3609-2a8c-43e8-9b5c-fc088082b15a Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2014 third_quarter PHA H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - ensuring that the pipeline for antibiotics is development in the country. Other issues related to improving availability and access to new antibiotics. Issues related to prescription drug abuse in the Medicare and Medicaid programs. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-09T10:38:45.543000-04:00
1583424 ROCK & ASSOCIATES ff4b5d3b-9b7a-416e-a79f-2981cd5cb6f0 Q3 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T14:17:05.490000-04:00
1583443 ROCK & ASSOCIATES 0169a0a6-e703-47fa-a98f-3c3fb8496d67 Q3 ROCK & ASSOCIATES 33545 CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE     0 0 2014-10-09T14:27:13.007000-04:00
1583448 ROCK & ASSOCIATES 4026feaf-0bf9-4513-ae06-88257dfd96bd Q3 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T14:32:14.040000-04:00
1583479 ROCK & ASSOCIATES ac81a849-c80d-4d29-af66-001d5e79a7a6 Q3 ROCK & ASSOCIATES 33545 TOWN & COUNTRY COMPOUNDING AND CONSULTING 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T14:53:21.923000-04:00
1583498 ROCK & ASSOCIATES 45ea663b-f12f-4308-8277-0a567d62fde4 Q3 ROCK & ASSOCIATES 33545 US COMPOUNDING 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T14:59:25.613000-04:00
1583513 ROCK & ASSOCIATES c3495503-a165-4434-82f9-60c698bc00cb Q3 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T15:04:29.397000-04:00
1583531 ROCK & ASSOCIATES 8fc93e38-9904-41a5-bfa0-74696176f5b2 Q3 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T15:10:32.227000-04:00
1583537 ROCK & ASSOCIATES c354c035-896f-436a-96f8-13d5f3daf7a3 Q3 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2014 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2014-10-09T15:15:34.007000-04:00
1583628 RED+BLUE STRATEGIES 65332d30-4a89-49e6-90e3-ce69c1bcb67d 3A RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2014 third_quarter PHA Policies related to stopping prescription medication diversion and abuse Issues related to the creation of a biosimilar marketplace in the United States Issues related to home delivery of prescription drugs Issues related to Part D coverage for Medicare beneficiaries in hospice care HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-09T16:50:00.180000-04:00
1583808 CHRISTY ELLERBEE CONSULTING, LLC ff36adb4-e728-40f8-ab16-1133d6e3ee72 Q3 CHRISTY ELLERBEE CONSULTING, LLC 401103332 INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) 2014 third_quarter PHA Pharmaceutical issues relevant to Reckitt Benckiser Pharmaceuticals, Inc. HOUSE OF REPRESENTATIVES,SENATE     0 0 2014-10-10T10:40:58.813000-04:00
1583814 ENDO INTERNATIONAL 59423de5-09e1-4fe5-89de-d3285ee24553 Q3 ENDO INTERNATIONAL 40011075 ENDO INTERNATIONAL 2014 third_quarter PHA Issues related to tamper resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act. HOUSE OF REPRESENTATIVES,SENATE   270000 0 0 2014-10-10T10:54:03.427000-04:00
1584022 PARRY, ROMANI, DECONCINI & SYMMS eb9f9e19-1dd6-460c-84e3-f18c1429b6bd Q3 PARRY, ROMANI, DECONCINI & SYMMS 30792 POZEN, INC. 2014 third_quarter PHA Support H.R.2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development. HOUSE OF REPRESENTATIVES,SENATE 36000   0 0 2014-10-10T14:38:20.850000-04:00
1584112 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 5f94be72-f6fc-4715-89f9-681cbbdf4319 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2014 third_quarter PHA HR 460, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1879 Cancer Treatment Parity Act. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2014-10-10T16:01:39.557000-04:00
1584133 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f8451ea1-e59f-403a-b3af-fe9a501c1704 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2014 third_quarter PHA issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-10T16:18:46-04:00
1584153 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 432abe85-89c6-4f26-b770-d7f697ab407a Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2014 third_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 460 Patients Access to Treatment Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2014-10-10T16:38:48.617000-04:00
1584187 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 302ca5d6-5052-4244-9f8f-73d1f0be1b64 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2014 third_quarter PHA Issues related to anti-epileptic drugs Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2014-10-10T17:01:55.487000-04:00
1584207 THE D MAJOR GROUP 7a30a25e-b762-424f-94aa-12979680e39e Q3 THE D MAJOR GROUP 401103162 CVS CAREMARK 2014 third_quarter PHA Issues concerning prescription drug abuse including H.R. 3392, The Medicare Part D Patient Safety & Drug Abuse Prevention Act; and H.R. 4069, The Ensuring Patient Access & Effective Drug Enforcement Act of 2014. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-10T18:31:08.893000-04:00
1584223 THE D MAJOR GROUP 92b261d3-97f2-4bba-89f1-0ed785525b45 Q3 THE D MAJOR GROUP 401103162 HEALTH CARE SUPPLY CHAIN ASSOCIATION 2014 third_quarter PHA Implementation issues concerning the Drug Quality and Supply Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-10T18:57:12.417000-04:00
1584544 ASSOCIATION OF NATIONAL ADVERTISERS, INC. f8110fc5-8761-47a0-bc53-6bdc75ba1639 Q3 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2014 third_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE   350000 0 0 2014-10-13T14:47:09.270000-04:00
1585471 VORYS ADVISORS, LLC ec6ff3ac-30ba-4925-8db2-33922cf28263 Q3 VORYS ADVISORS, LLC 400873558 AMERISOURCEBERGEN CORPORATION 2014 third_quarter PHA Various health care proposals HOUSE OF REPRESENTATIVES     0 0 2014-10-14T13:31:50.427000-04:00
1585782 RED+BLUE STRATEGIES d8337ee6-301a-4080-9e29-d52b5b6841d8 Q3 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2014 third_quarter PHA Issues related to opioid abuse and programs that can successfully combat the problem. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-14T15:21:45.027000-04:00
1585830 BROWN RUDNICK LLP fb8bf7e4-5cb6-4dc3-9eae-88a616835f55 Q3 BROWN RUDNICK LLP 287895 AMNEAL PHARMACEUTICALS 2014 third_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-14T15:57:55.680000-04:00
1585892 UNIVERSITY OF IOWA 7672d2b0-3370-4a85-929e-4eaa5dffa7c4 Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2014 third_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   85562 0 0 2014-10-14T16:19:10.483000-04:00
1585978 ABRAHAM & ROETZEL, LLC cc1e2be8-e919-49c3-bf10-d756304fb08c Q3 ABRAHAM & ROETZEL, LLC 400954757 MATCHRX 2014 third_quarter PHA Drug Quality and Security Act. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2014-10-14T17:05:32.357000-04:00
1586043 MR. GALEN RESER 7d35e459-e487-4eea-9359-933cfb2c45a6 Q3 MR. GALEN RESER 401055978 PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) 2014 third_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, H.R. 2835, "Restoring Access to Medication Act of 2013." FDA's proposed changes to generic drug labeling. FDA's proposed Infant Formula regulations. House Energy and Commerce 21st Century Cures Initiative. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2014-10-14T18:16:48.977000-04:00
1586094 RUBICON ADVISORS, LLC f80d3fe0-976b-4ada-af5a-8be83ade1b89 Q3 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2014 third_quarter PHA Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2014-10-14T22:39:06.887000-04:00
1586095 RUBICON ADVISORS, LLC 402512e2-e435-40ce-aa4d-e4de16e3a95a Q3 RUBICON ADVISORS, LLC 315091 ALLIANCE TO PREVENT THE ABUSE OF MEDICINES 2014 third_quarter PHA Prescription Drug Abuse Policy HOUSE OF REPRESENTATIVES,SENATE 105000   0 0 2014-10-14T22:44:07.857000-04:00
1586096 RUBICON ADVISORS, LLC 92f2ea62-07ce-46e2-aacc-442f380f23f4 3T RUBICON ADVISORS, LLC 315091 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2014 third_quarter PHA Physician Payment Sunshine Act S 2029 Patent Settlements H.R. 14328 .316 Affordable Healthcare Choices Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 1 2014-10-14T22:47:08.843000-04:00
1586099 RUBICON ADVISORS, LLC f21ed720-cf2e-4c0d-b60a-8a6497871ce1 Q3 RUBICON ADVISORS, LLC 315091 COLLEGE OF AMERICAN PATHOLOGISTS 2014 third_quarter PHA Physician Payment rates, Electronic Health Records Incentives Program HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-14T22:56:14.377000-04:00
1586100 RUBICON ADVISORS, LLC 2c09edc4-fd76-4636-9023-4aebff9d6e5d Q3 RUBICON ADVISORS, LLC 315091 STATE MUTUAL INSURANCE COMPANY 2014 third_quarter PHA Pharmacy Compounding HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-14T22:59:15.177000-04:00
1586501 SCONSET STRATEGIES, LLC 030a362b-bc79-4d6f-94bb-20eb794f29cb Q3 SCONSET STRATEGIES, LLC 400794388 FREEMAN ALLERGY, INC. 2014 third_quarter PHA Issues related to securing additional clinical trials nationally and internationally. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2014-10-15T11:07:54.150000-04:00
1586880 VALENTE & ASSOCIATES 3eddf118-06cb-4411-a392-68fd1590addb Q3 VALENTE & ASSOCIATES 45983 SAV-MOR FRANCHISING, INC. 2014 third_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES 30000   0 0 2014-10-15T14:15:38.147000-04:00
1586989 BROWN RUDNICK LLP 3131cc7d-04fd-483e-9866-114142859409 3A BROWN RUDNICK LLP 287895 AMNEAL PHARMACEUTICALS 2014 third_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-15T14:42:07.597000-04:00
1587164 BROWN RUDNICK LLP d949be25-c821-4795-ba4e-7b123c4a906d Q3 BROWN RUDNICK LLP 287895 EXELA HOLDINGS, LLC 2014 third_quarter PHA Implementation of P.L. 112-144 (FDA Safety and Innovation Act) and P.L. 113 - 54 (Drug Quality and Security Act); Issues relating to ANDA approval Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-15T15:25:44.860000-04:00
1588066 APOTEX CORP. 90aba804-470a-4c3e-96a3-54136069acd5 Q3 APOTEX CORP. 310973 APOTEX CORP. 2014 third_quarter PHA FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; HR 5657, the Fair Acess for Safe and Timely Generics Act of 2014, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative; Federal policy relating to International Nonroprietary Names for Biosimilars; and, Implementation of Public Law 112-144 - The Food and Drug Administration Safety and Innovation Act, federal policy relating to provisions in Title 3 regarding generic drug user fees. HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2014-10-16T09:31:46.353000-04:00
1588476 SANOFI US SERVICES INC. 5d6f309b-7808-4915-ae12-4a8ea622ddbe Q3 SANOFI US SERVICES INC. 56838 SANOFI US SERVICES INC 2014 third_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE   940000 0 0 2014-10-16T11:18:08.343000-04:00
1588483 EXPRESS SCRIPTS, INC. 1b815530-d438-4d40-bbd1-a4dfe87fbf7c Q3 EXPRESS SCRIPTS, INC. 294416 EXPRESS SCRIPTS, INC. 2014 third_quarter PHA Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office   500000 0 0 2014-10-16T11:21:09.860000-04:00
1589017 NOVO NORDISK INC. c8b3c246-79ce-497c-bff8-3c6f36ba8b4f Q3 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2014 third_quarter PHA HR 3204, S. 959 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; 340B Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA)   910000 0 0 2014-10-16T13:23:49.780000-04:00
1589376 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION a06ab644-734c-4a77-a512-7dee5269d3a9 Q3 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2014 third_quarter PHA Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 H.R. 4160, Keep the Promise to Seniors Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid; Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data Act to Medicare/Medicaid Administration for Children & Families (ACF),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   788458 0 0 2014-10-16T14:25:06.393000-04:00
1589431 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION cf7d6ef2-4914-4664-864f-d32e41f704b3 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2014 third_quarter PHA Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC SwitchSupporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R. 4250/S. 2141 - Sunscreen Innovation Act. Would require FDA to approve or deny new sunscreen ingredient applications under the "time and extent" application (TEA) process within a certain timeframe after submission; all sections. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   220000 0 0 2014-10-16T14:30:16.803000-04:00
1589486 CUBIST PHARMACEUTICALS, INC. 21725fa6-0294-47c9-a620-84e61e8d267b Q3 CUBIST PHARMACEUTICALS, INC. 40026226 CUBIST PHARMACEUTICALS 2014 third_quarter PHA Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; HR 3742- the Antibiotic Development to Advance Patient Treatment Act of 2013; H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014;antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort HOUSE OF REPRESENTATIVES,SENATE   450000 0 0 2014-10-16T14:36:26.210000-04:00
1589696 WHITMER & WORRALL, LLC e247e962-a2ec-4354-8014-029e6f849c51 Q3 WHITMER & WORRALL, LLC 292892 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2014 third_quarter PHA Issues related to The Patient Protection and Affordable Care Act (Public Law 111 148) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-16T15:09:04.130000-04:00
1589749 PD FRAZER CONSULTING, INC. 41906f9b-8c92-40c6-8a1d-cc26294a06be Q3 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2014 third_quarter PHA Monitor the development of proposed bills about the importation of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2014-10-16T15:20:55.430000-04:00
1589825 NELSON MULLINS RILEY & SCARBOROUGH 1aa503a1-e391-4caa-b699-73ce7875d7f5 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 TRANSDERMAL THERAPEUTICS, INC. 2014 third_quarter PHA Issues related to Tricare reimbursements HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2014-10-16T15:36:26.217000-04:00
1590467 GREATER NEW YORK HOSPITAL ASSOCIATION a455fc83-f556-40f4-85ce-0d9a54fea95f Q3 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2014 third_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; opposing the current HRSA guidance on the 340b drug pricing GPO exclusion (HRSA Release 2013-1); opposing taxes on mobile health applications (FDA mobile health guidance and regulatory risk-based framework, FDA-2011-D-0530, FDA-2014-N-0339); comments on regulations affecting point-of-use care for glucose monitoring systems (FDA-2013-D-1445); educating policy makers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (HR5435) - support; and comments on Medicare physician services pertaining to non-face-to face chronic care management services (CMS- 1612-P). Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),SENATE,White House Office   270000 0 0 2014-10-16T17:23:09.660000-04:00
1590598 KAISER FOUNDATION HEALTH PLAN INC. 5f3d3b98-6990-49df-a9eb-aad3e98fb567 Q3 KAISER FOUNDATION HEALTH PLAN INC. 21027 KAISER FOUNDATION HEALTH PLAN INC 2014 third_quarter PHA HR 4095 & S 2002 - Online Pharmacy Safety Act: To amend the Federal Food, Drug and Cosmetic Act to improve the safety of Internet pharmacies. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2014-10-16T17:58:35.557000-04:00
1590655 MR. THEODORE (TED) JONES 223e08f8-c622-4056-b111-95f35de4be1f Q3 MR. THEODORE (TED) JONES 20926 COQUI RADIOPHARMACEUTICALS, CORP. 2014 third_quarter PHA American Medical Isotopes Production Act of 2012 that was contained in teh National Defense Authorization Act for Fiscal Year 2013 Acceleration of production on 99 MO using LEU (Low Enriched Uranium). HOUSE OF REPRESENTATIVES,SENATE 49134   0 0 2014-10-16T18:09:41.433000-04:00
1590743 CROSSROADS STRATEGIES, LLC a80a223d-d087-44f6-bb70-eaec1fd4d3a3 Q3 CROSSROADS STRATEGIES, LLC 400531586 LUMARA HEALTH 2014 third_quarter PHA Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-16T19:02:50.517000-04:00
1590829 GOVBIZ ADVANTAGE, INC. 377f40f4-128c-4335-8b3f-d80e73d62eba Q3 GOVBIZ ADVANTAGE, INC. 294234 WHITE HOUSE CONSULTING (FOR SYMBIOMIX) 2014 third_quarter PHA GAIN Act qualification for a drug HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2014-10-16T21:31:16.523000-04:00
1591172 BLUESTONE STRATEGIES, LLC 3850842a-6b6d-4140-84d1-11867f161c83 Q3 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2014 third_quarter PHA Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2014-10-17T09:19:28.847000-04:00
1591267 ACADEMY OF MANAGED CARE PHARMACY 001bd9cb-2c2b-4bea-b4ac-5fda62c9a7e9 3A ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2014 third_quarter PHA Biosimilar naming - supporting Congressional action to seek FDA decision on biosimiar naming and supporting FTC study of effect of naming on competition. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   210000 0 0 2014-10-17T09:49:53.887000-04:00
1591390 NELSON MULLINS RILEY & SCARBOROUGH 8b160c56-3058-45d9-9a9c-d50da08d975b Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2014 third_quarter PHA Any legislation and regulation relating to the treatment of opioid abuse HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2014-10-17T10:12:57.787000-04:00
1591405 NELSON MULLINS RILEY & SCARBOROUGH 3b64878d-9971-4245-8185-d26a65d7f0f1 3A NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2014 third_quarter PHA Any legislation and regulation relating to the treatment of opioid abuse HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2014-10-17T10:14:01.160000-04:00
1591572 OREGON HEALTH & SCIENCE UNIVERSITY d9d15223-e94c-4dac-99fe-c39acfaad200 Q3 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2014 third_quarter PHA 340b Drug Discount program for safety net hospitals Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2014-10-17T10:48:57.610000-04:00
1591645 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 416278ed-6c5c-43a3-80ce-54c905c2fdbf Q3 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 1967 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 2014 third_quarter PHA H.R.3089 - Compounding Clarity Act H.R.3528 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 S.1323 - Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013 HOUSE OF REPRESENTATIVES,SENATE   291063 0 0 2014-10-17T10:55:11.020000-04:00
1591715 WILLIAMS AND JENSEN, PLLC de0925fe-6d29-4f60-b1b0-5601cd5913b7 Q3 WILLIAMS AND JENSEN, PLLC 41454 PHARMACY SERVICES 2014 third_quarter PHA Regulations of compounding pharmacies. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-17T11:01:27.960000-04:00
1591854 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ef53f374-cea9-4fc8-8c7d-ef09dd7bfc73 Q3 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2014 third_quarter PHA Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (HR 3204). Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   80000 0 0 2014-10-17T11:19:03.757000-04:00
1591877 EMPIRE CONSULTING GROUP 15306be3-480e-4953-aa25-b9b4fbb4e7b6 Q3 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2014 third_quarter PHA Issues relating to the Medicare Prescription Drug Act; 340B Drug Pricing Program. HOUSE OF REPRESENTATIVES 40000   0 0 2014-10-17T11:21:06.940000-04:00
1591960 RED+BLUE STRATEGIES f7d315fb-913a-44f9-8082-cf9478ccc536 Q3 RED+BLUE STRATEGIES 400693064 HOSPIRA 2014 third_quarter PHA Issues related to creating a new marketplace for biosimilar medications in the United States. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Office of Management & Budget (OMB) 30000   0 0 2014-10-17T11:31:07.360000-04:00
1592041 340B HEALTH 1df8dedd-fd8c-40fb-a0f5-5def4708e8ed Q3 340B HEALTH 316434 340B HEALTH 2014 third_quarter PHA FY15 Labor-HHS Appropriations, Orphan Drug Rule, 340B Drug Discount Program Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   244928 0 0 2014-10-17T11:43:44.490000-04:00
1592146 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 6b7d0647-d461-4665-9583-39b715493bf0 Q3 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 401097063 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 2014 third_quarter PHA --Support grant funding for trauma and emergency medical services for trauma hospitals -- Support readmissions policy to include socioeconomic factors --340B Program support to maintain current level of funding and discounts Funding for trauma and emergency services grant to hospitals H.R. 4188 and S. 2501- Readmissions policies must include socioeconomic factors H.R. 1250/S. 1012-Medicare Audit Improvement Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   15860 0 0 2014-10-17T11:53:45.587000-04:00
1592245 KOUNTOUPES DENHAM CARR & REID, LLC 9a0d21cf-7a80-4863-a417-868f3443d284 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2014 third_quarter PHA General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014. Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2014-10-17T12:04:03.480000-04:00
1592432 ANIMAL HEALTH INSTITUTE 35b9e477-396c-4f89-93b0-add66218301f Q3 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2014 third_quarter PHA FDA approval process; Unlicensed veterinary biologicals: Categorical Exclusions from Environmental Risk Assessments, Issues related to illegal drug manufacturing under the guise of compounding, HR4023 & S2756 - Fairness to Pet Owners Act HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2014-10-17T12:25:24.427000-04:00
1592951 MEHLMAN CONSULTING, INC. 572f780d-021c-4953-8fc4-f721f30d6e6a Q3 MEHLMAN CONSULTING, INC. 284950 WALMART INC 2014 third_quarter PHA Discussion on implementation of Medicare Part D and the Affordable Care Act. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2014-10-17T13:32:44.940000-04:00
1593107 TCH GROUP, LLC 0bcd3a3b-ab63-4692-aab2-982aa4e85cf5 Q3 TCH GROUP, LLC 51478 SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC ) 2014 third_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2014-10-17T13:48:25.350000-04:00
1593356 BLUECROSS BLUESHIELD OF TENNESSEE 323e3539-6371-4257-bb3e-90ba165ab50b Q3 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2014 third_quarter PHA General Pharmacy Issues HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2014-10-17T14:13:52.953000-04:00
1593585 BUCHANAN INGERSOLL & ROONEY PC 6ac0f175-7ec6-4737-bde6-110270519c23 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 WOCKHARDT LTD 2014 third_quarter PHA Strategy development and implementation of federal government relations initiatives; HR 3742, Antibiotic Development to Advance Patient Treatment; FDA compliance issues; HR 1919, Drug Supply Chain Security Act HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2014-10-17T14:33:38.290000-04:00
1593657 CAPITOL HILL CONSULTING GROUP 4dc9b6b9-90e9-497c-84d8-4e2514c24c0e Q3 CAPITOL HILL CONSULTING GROUP 72053 ENDO PHARMACEUTICALS 2014 third_quarter PHA Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825) HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2014-10-17T14:38:37.493000-04:00
1593683 BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ a6a8d319-98bb-4ef2-bde3-3f439442f8b1 Q3 BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ 5153 GENERIC PHARMACEUTICAL ASSOCIATION 2014 third_quarter PHA Issues relating to biosimilar regulation HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2014-10-17T14:40:45.087000-04:00
1593810 HANCE SCARBOROUGH 64806ec8-c9ed-45ea-9eb4-e98381a3c37d Q3 HANCE SCARBOROUGH 17443 ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS 2014 third_quarter PHA Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2014-10-17T14:50:35.090000-04:00
1593935 AMERICAN VETERINARY MEDICAL ASSOCIATION 4f915521-d2e7-483d-abd5-bea7eb4c6f81 Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2014 third_quarter PHA H.R. 1150 Preservation of Antibiotics for Medical Treatment Act S. 1256 Prevent Antibiotic Resistance Act H.R. 1528/S. 1171 Veterinary Medicine Mobility Act H.R. 4023 Fairness to Pet Owners Act Animal Compounding Veterinary Feed Directive Discussions with Congressional staff about DEA regulations impeding practice of veterinary medicine; seeking passage of legislation to change underlying statute (H.R. 1528) Discussions with Congressional staff and FDA regarding the use of antimicrobials in feed producing animals, particularly with respect to H.R. 1150 (Preservation of Antibiotics for Medical Treatment Act), S. 1256 (Preventing Antibiotic Resistance Act), and FDA's strategy. Discussions with Congressional staff, FDA and Government Accountability Office expressing the need for compounding of medications for use in animals. Inquiries to and discussions with Congressional staff and Federal Trade Commission on veterinary pet prescriptions, particularly regarding H.R. 4023/S. 2756 (Fairness to Pet Owners Act) Agriculture, Dept of (USDA),Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   210000 0 0 2014-10-17T14:55:59.387000-04:00
1594046 AMERICAN VETERINARY MEDICAL ASSOCIATION c0b5dea4-4293-4926-9fc7-5915ff2b4618 3A AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2014 third_quarter PHA H.R. 1150 Preservation of Antibiotics for Medical Treatment Act S. 1256 Prevent Antibiotic Resistance Act H.R. 1528/S. 1171 Veterinary Medicine Mobility Act H.R. 4023 Fairness to Pet Owners Act Animal Compounding Veterinary Feed Directive Discussions with Congressional staff about DEA regulations impeding practice of veterinary medicine; seeking passage of legislation to change underlying statute (H.R. 1528) Discussions with Congressional staff and FDA regarding the use of antimicrobials in feed producing animals, particularly with respect to H.R. 1150 (Preservation of Antibiotics for Medical Treatment Act), S. 1256 (Preventing Antibiotic Resistance Act), and FDA's strategy. Discussions with Congressional staff, FDA and Government Accountability Office expressing the need for compounding of medications for use in animals. Inquiries to and discussions with Congressional staff and Federal Trade Commission on veterinary pet prescriptions, particularly regarding H.R. 4023/S. 2756 (Fairness to Pet Owners Act) Agriculture, Dept of (USDA),Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   210000 0 0 2014-10-17T15:03:14.657000-04:00
1594109 BLUE CROSS AND BLUE SHIELD ASSOCIATION 8efbd9f0-3bef-4ee0-8642-16e5a3169779 Q3 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2014 third_quarter PHA Prescription Drugs Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   1540000 0 0 2014-10-17T15:08:04.893000-04:00
1594137 THORSEN FRENCH ADVOCACY LLC 40bd36fe-4f6c-4d16-a9fe-743ef88b1858 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 ASTRAZENECA PHARMACEUTICALS LP 2014 third_quarter PHA Issues related to access to pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-17T15:11:17.113000-04:00
1594182 CAPITOL HILL CONSULTING GROUP 7406df1a-87e2-46c2-95e8-7000e59e7513 Q3 CAPITOL HILL CONSULTING GROUP 72053 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2014 third_quarter PHA Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2014-10-17T15:13:24.520000-04:00
1594200 BROWN RUDNICK LLP 9b9d12fb-f0e3-45e7-a247-78ea5aa3e383 Q3 BROWN RUDNICK LLP 287895 HOSPIRA, INC. 2014 third_quarter PHA Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94). HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2014-10-17T15:14:34.880000-04:00
1594293 BROWN RUDNICK LLP 9774d8c9-c2d7-419c-bf6e-8b8ef4966a1b Q3 BROWN RUDNICK LLP 287895 APOTEX CORPORATION 2014 third_quarter PHA Issues relating to Risk Evaluation and Mitigation Strategy programs; Generic Drug User Fee Amendments of 2012 (GDUFA); Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94). HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2014-10-17T15:21:56.507000-04:00
1594385 BROWN RUDNICK LLP 66ba298f-1229-491a-8f0d-1aef38ee65e0 Q3 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2014 third_quarter PHA H.R. 4709 - Ensuring Patient Access and Effective Drug Enforcement Act; S. 2862-The Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4299 - Improving Regulatory Transparency for New Medical Therapies Act; Implementation of P.L. 113 - 54 (Drug Quality and Security Act) HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2014-10-17T15:27:17.587000-04:00
1594448 CAPITOL HILL CONSULTING GROUP 57e44d4f-fe93-4b6f-9905-0188a9f820ad Q3 CAPITOL HILL CONSULTING GROUP 72053 WELLNESS PHARMACY 2014 third_quarter PHA Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2014-10-17T15:31:16.057000-04:00
1594479 BROWN RUDNICK LLP 8fd833e4-d5f2-4581-874b-88e3fa10c674 Q3 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2014 third_quarter PHA Issues relating to prescription drug abuse and diversion; HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014 Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2014-10-17T15:32:38.743000-04:00
1594549 AMERICAN ACADEMY OF FAMILY PHYSICIANS 0b313d8e-bfba-4378-86a0-6d98d183f83f Q3 AMERICAN ACADEMY OF FAMILY PHYSICIANS 1342 AMERICAN ACADEMY OF FAMILY PHYSICIANS 2014 third_quarter PHA HR 3528, National All Schedules Prescription Electronic Reporting Reauthorization Act, Prevent opiod abuse, encourage adequate pain management; Support reauthorization of NASPER to provide immediate information about perscription use. S. 2529, National All Schedules Prescription Electronic Reporting Reauthorization Act, Prevent opiod abuse, encourage adequate pain management; Support reauthorization of NASPER to provide immediate information about perscription use. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office   1924466 0 0 2014-10-17T15:36:37.480000-04:00
1594558 ARNOLD & PORTER KAYE SCHOLER LLP 9fb775fd-6f92-490d-8dc6-e9c174161631 Q3 ARNOLD & PORTER KAYE SCHOLER LLP 4301 INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS 2014 third_quarter PHA Issues related to the regulation of the practice of pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2014-10-17T15:36:39.793000-04:00
1594606 BROWN RUDNICK LLP 0c6f9a13-d7be-4db9-81f6-e8335d1be403 Q3 BROWN RUDNICK LLP 287895 MEDTRONIC INC 2014 third_quarter PHA S. 2825 relating to the delivery of a controlled substance by a pharmacy to a practitioner HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2014-10-17T15:38:58.967000-04:00
1594617 CAPITOL HILL CONSULTING GROUP f28d5eb3-dd69-4b2d-ab18-08f89d5c0675 Q3 CAPITOL HILL CONSULTING GROUP 72053 PURDUE PHARMA LLP 2014 third_quarter PHA Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2014-10-17T15:39:45.560000-04:00
1594678 BROWN RUDNICK LLP c56633ad-de59-4e25-90ed-0102b861ea1e Q3 BROWN RUDNICK LLP 287895 ZYDUS PHARMACEUTICALS USA INC. 2014 third_quarter PHA Issues relating to FDA generic drug approval; Generic Drug User Fee Amendments of 2012 (GDUFA) HOUSE OF REPRESENTATIVES 30000   0 0 2014-10-17T15:44:16.187000-04:00
1594787 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 209d9284-9654-4a00-872f-c01f902d2950 Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2014 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on the labeling of generic medications and biosimilars. Communication with FTC on biosimilars. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2014-10-17T15:54:21.893000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1759.936ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API